TD Cowen analyst Joshua Jennings raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $70 and keeps a Hold rating on the shares. The firm noted the company offered a favorable multiyear outlook at its annual investor day. The company reiterated its 2024 guidance and introduced 2025 guidance that brackets the Street’s current estimates.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $68 from $63 at Canaccord
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%
- Edwards Lifesciences price target raised to $88 from $85 at Barclays